Geoffrey R. Oxnard
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment, RNA modifications and cancer
Most-Cited Works
- → Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M(2015)1,518 cited
- → Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA(2020)1,444 cited
- → Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review(2018)897 cited
- → Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer(2016)838 cited
- → Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer(2020)816 cited
- → Noninvasive Detection of Response and Resistance in EGFR -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA(2014)776 cited
- → MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression(2016)681 cited
- → Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib(2018)677 cited
- → Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer(2015)660 cited
- → Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation(2010)623 cited